HOLX$75.605
Chart
Performance
Key Stats
AI HOLX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyHologic Inc. demonstrates solid fundamental performance, particularly in profitability and a manageable debt level. While thematic tailwinds in women's health are present, current valuation metrics and mixed technical signals suggest a balanced approach for investors. It presents a good opportunity for long-term investors focused on healthcare innovation.
Thematic
Hologic operates in the growing women's health sector, benefiting from increased awareness and investment in diagnostics and medical devices. However, its thematic strength is somewhat constrained by competition and the specialized nature of its market.
Fundamental
Hologic demonstrates robust profitability and a healthy balance sheet with manageable debt. Revenue and net income have shown resilience, although recent trends indicate a slight slowdown, necessitating monitoring of future growth drivers. Valuation multiples are reasonable given its profitability.
Technical
The stock shows mixed technical signals. While it is trading above key moving averages, indicating some underlying strength, momentum oscillators suggest a neutral to slightly cautious stance. Immediate price action is relatively stable.
| Factor | Score |
|---|---|
| Women's Health Market Growth | 85 |
| Innovation in Diagnostics | 80 |
| Regulatory Environment (Healthcare) | 65 |
| Global Market Penetration | 70 |
| Competition in Medical Devices | 55 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 85 |
| Growth | 50 |
| Balance Sheet Health | 70 |
| Cash Flow | 85 |
| Earnings Consistency | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 65 |
| Volume | 70 |
| Support & Resistance | 60 |
| Short-term Oscillators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Momentum
The stock price has shown a slight increase of 0.23% today, indicating positive short-term price momentum.
Strong 5-Day Performance
The stock has gained 3.78% over the last 5 days, suggesting recent positive investor sentiment.
Bearish Points (7)
Negative Year-to-Date and Annual Performance
The stock has experienced a decline of 7.86% year-to-date and 15.94% over the past year, indicating underperformance and potential headwinds.
High Price-to-Sales Ratio
The P/S ratio for 2024 is 4.5, which might be considered high, suggesting potential overvaluation relative to revenue.
Calendar
July 2025
31
Next Earnings Date
H: $1.06
A: $1.05
L: $1.04
H: 1.02B
A: 1.01B
L: 1.00B
Profile
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Seasonals
Price Target
70.07 USD
The 39 analysts offering 1 year price forecasts for HOLX have a max estimate of 80.00 and a min estimate of 65.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in molecular diagnostics, sample and assay technologies, and automated solutions, serving similar lab and healthcare customers.
Weight: 90
Specializes in cancer diagnostics, including early detection and precision oncology, overlapping with Hologic's diagnostic focus on women's cancer.
Weight: 88
Diversified healthcare company with a significant presence in diagnostics (e.g., infectious disease, molecular) and medical devices, a broad competitor.
Weight: 85
Global science and technology innovator with strong positions in life sciences and diagnostics platforms, a key competitor in the broader diagnostics market.